


**LABORATORIES LTD.**

Fax No : 91 (22) 2678 4391 / 5198

Tel. No. : 91 (22) 6688 8333

Website : http://www.unichemlabs.com

Registered &amp; Corporate Office : Unichem Bhavan, Prabhat Estate, S. V. Road, Jogeshwari (West), Mumbai-400102, INDIA.

PART I						
Statement of Standalone Unaudited Results for the Quarter and Half year ended 30th September, 2012.						
Particulars	Three months ended 30th Sep'12 (Unaudited)	Three months ended 30th Jun'12 (Unaudited)	Three months ended 30th Sep'11 (Unaudited)	Half year ended 30th Sep'12 (Unaudited)	Half year ended 30th Sep'11 (Unaudited)	₹ Lacs Accounting Year ended 31st Mar'12 (Audited)
<b>INCOME FROM OPERATIONS</b>						
1 a) Net Sales/Income from operations (Net of excise duty)	26,116.57	26,329.95	19,708.98	52,446.52	38,376.83	79,390.96
b) Other Operating Income	308.11	156.15	174.90	464.26	381.90	927.77
<b>TOTAL INCOME FROM OPERATIONS (NET)</b>	<b>26,424.68</b>	<b>26,486.10</b>	<b>19,883.88</b>	<b>52,910.78</b>	<b>38,758.73</b>	<b>80,318.73</b>
<b>EXPENSES</b>						
a) Cost of Material Consumed	6,104.59	7,222.82	3,871.68	13,327.11	7,559.44	10,290.78
b) Purchases of stock-in-trade	2,827.78	3,356.73	2,327.00	6,184.51	5,559.44	10,290.78
c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	754.08	(293.89)	935.77	460.19	682.14	(202.58)
d) Employee benefits' expense	3,593.61	3,378.59	3,029.06	6,972.20	6,003.74	11,892.04
e) Depreciation and amortisation expense	820.87	827.61	690.71	1,648.48	1,364.74	2,828.81
f) Other expenses	7,851.71	8,041.58	6,679.73	15,683.13	12,914.87	26,167.20
<b>TOTAL EXPENSES</b>	<b>21,952.64</b>	<b>22,533.44</b>	<b>17,533.96</b>	<b>44,275.92</b>	<b>34,391.98</b>	<b>70,404.80</b>
3 <b>Profit/(Loss) from operations before other income, finance costs and exceptional items (1-2)</b>	<b>4,472.04</b>	<b>3,952.66</b>	<b>2,349.92</b>	<b>8,634.86</b>	<b>4,366.75</b>	<b>9,913.93</b>
4 Other Income	218.64	685.32	332.89	693.80	515.63	939.47
5 <b>Profit/(Loss) from ordinary activities before finance costs and exceptional items (3+4)</b>	<b>4,690.68</b>	<b>4,637.98</b>	<b>2,682.81</b>	<b>9,328.66</b>	<b>4,882.38</b>	<b>10,853.40</b>
6 Finance costs	66.39	85.76	86.60	152.15	134.38	329.85
7 <b>Profit/(Loss) from ordinary activities after finance costs but before exceptional items (5-6)</b>	<b>4,624.29</b>	<b>4,552.22</b>	<b>2,596.21</b>	<b>9,176.51</b>	<b>4,748.00</b>	<b>10,523.55</b>
8 Exceptional Items	-	-	-	-	-	-
9 <b>Profit/(Loss) from ordinary activities before tax (7-8)</b>	<b>4,624.29</b>	<b>4,552.22</b>	<b>2,596.21</b>	<b>9,176.51</b>	<b>4,748.00</b>	<b>10,523.55</b>
10 Tax Expenses (Including Deferred tax)	1,117.00	1,238.00	682.00	2,355.00	1,272.00	2,281.00
11 <b>Net profit from ordinary activities after tax (9-10)</b>	<b>3,507.29</b>	<b>3,314.22</b>	<b>1,914.21</b>	<b>6,821.51</b>	<b>3,476.00</b>	<b>8,242.55</b>
12 Prior period Expenses / (Income)	-	-	-	-	-	-
13 Excess / (Short) provision for taxation pertaining to earlier years.	-	-	-	-	-	3.78
14 <b>Net profit from ordinary activities after tax and prior period items (11-12-13)</b>	<b>3,507.29</b>	<b>3,314.22</b>	<b>1,914.21</b>	<b>6,821.51</b>	<b>3,476.00</b>	<b>8,246.33</b>
15 Extraordinary items (net of tax expense)	-	-	-	-	-	-
16 <b>Net profit for the period (14-15)</b>	<b>3,507.29</b>	<b>3,314.22</b>	<b>1,914.21</b>	<b>6,821.51</b>	<b>3,476.00</b>	<b>8,246.33</b>
17 Paid up Equity Share Capital (Face Value Rs. 2 per share)	1,808.96	1,806.64	1,806.07	1,808.96	1,806.07	1,806.43
18 Reserves & Surplus excluding Revaluation Reserve as per balance sheet of previous accounting year.	-	-	-	-	-	71,195.27
19 a) Basic Earnings per share-not annualised before & after extraordinary items - Rs.	3.88	3.67	2.12	7.55	3.85	9.13
b) Diluted earnings per share after Employees Stock Options before & after extraordinary items - Rs.	3.87	3.65	2.11	7.52	3.83	9.09

**UNICHEM-A TRUSTED NAME IN PHARMACEUTICALS**


**LABORATORIES LTD.**

Fax No : 91 (22) 2678 4391 / 5198

Tel. No. : 91 (22) 6688 8333

 Website : <http://www.unichemlabs.com>
**Registered & Corporate Office :** Unichem Bhavan, Prabhat Estate, S. V. Road, Jogeshwari (West), Mumbai-400102,INDIA.

Particulars	Three months ended 30th Sep'12 (Unaudited)	Three months ended 30th Jun'12 (Unaudited)	Three months ended 30th Sep'11 (Unaudited)	Half year ended 30th Sep'12 (Unaudited)	Half year ended 30th Sep'11 (Unaudited)	Accounting Year ended 31st Mar'12 (Audited)
<b>PART II</b>						
<b>A. PARTICULARS OF SHAREHOLDING</b>						
<b>1 Public Shareholding</b>						
Number of Shares	45,651,886	45,535,761	45,831,370	45,651,886	45,831,370	45,537,639
Percentage of Shareholding	50.47%	50.41%	50.75%	50.47%	50.75%	50.42%
<b>2 Promoters and Promoters group shareholding</b>						
a) Pledged /Encumbered						
- Number of Shares	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of shares ( as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil	Nil	Nil
- Percentage of shares (as a % of the total share capital of the company)	Nil	Nil	Nil	Nil	Nil	Nil
b) Non- encumbered						
- Number of Shares	44,796,240	44,796,241	44,472,319	44,796,240	44,472,319	44,783,863
- Percentage of shares ( as a % of the total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
- Percentage of shares (as a % of the total share capital of the company)	49.53%	49.59%	49.25%	49.53%	49.25%	49.58%

Particulars	Quarter Ended 30.09.2012
<b>B. INVESTOR COMPLAINTS</b>	
Pending at the beginning of the quarter	NIL
Received during the quarter	3
Disposed of during the quarter	3
Remaining unresolved at the end of the quarter	NIL

**Notes :**

1 The above results have been subjected to Limited Review by the Statutory Auditors ,reviewed by the Audit Committee and taken on record by the Board of Directors of the Company in its meeting held on 20th October, 2012.

2 Segment Reporting:

*Primary Segment*

The Company has only one segment i.e. 'Pharmaceuticals'.

*Secondary Segment (By Geographical Segment)*

Net Sales and Operating Income	Three months ended 30th Sep 2012	Three months ended 30th Jun 2012	Three months ended 30th Sep 2011	Half year ended 30th Sep 2012	Half year ended 30th Sep 2011	Accounting Year ended 31st Mar 2012
Within India	17,710.42	17,657.12	14,836.96	35,367.54	29,230.16	55,658.03
Outside India	8,714.26	8,828.98	5,046.92	17,543.24	9,528.57	24,860.70
<b>Total</b>	<b>26,424.68</b>	<b>26,486.10</b>	<b>19,883.88</b>	<b>52,910.78</b>	<b>38,758.73</b>	<b>80,318.73</b>

In view of the interwoven / intermix nature of the business and manufacturing facility, other segmental information is not ascertainable.


**UNICHEM LABORATORIES LTD.**

Registered & Corporate Office : Unichem Bhavan, Prabhat Estate, S. V. Road, Jogeshwari (West), Mumbai-400102, INDIA.

3 Other expenses / Other income includes exchange gain / loss as under :						₹ Lacs
Exchange Difference	Three months ended 30th Sep 2012	Three months ended 30th Jun 2012	Three months ended 30th Sep 2011	Half year ended 30th Sep 2012	Half year ended 30th Sep 2011	Accounting Year ended 31st Mar 2012
Exchange gain included in Other Income	-	559.30	178.65	349.14	232.64	294.93
Exchange loss included in Other Expenses	210.16	-	-	-	-	-

**4 Unaudited Statement of Assets and Liabilities.**

₹ Lacs

Particulars	As at 30th Sept 2012	As at 30th Sept 2011
<b>I. EQUITY AND LIABILITIES</b>		
<b>(1) Shareholders' Fund</b>		
(a) Share Capital	1,808.96	1,806.07
(b) Reserve & Surplus	78,104.15	69,534.94
	<b>79,913.11</b>	<b>71,341.01</b>
(2) Share Application Money pending	-	1.73
<b>(3) Non Current Liabilities</b>		
(a) Long term borrowings	2,475.73	2,347.38
(b) Deferred tax liabilities (Net)	4,147.43	4,081.43
(c) Long term provisions	1,329.75	1,080.36
	<b>7,952.91</b>	<b>7,509.17</b>
<b>(4) Current Liabilities</b>		
(a) Short term borrowings	46.95	2,415.74
(b) Trade payables	16,746.11	11,640.39
(c) Other current liabilities	3,700.83	3,509.67
(d) Short-term provisions	651.03	-
	<b>21,144.92</b>	<b>17,565.80</b>
<b>TOTAL EQUITY AND LIABILITIES</b>	<b>109,010.94</b>	<b>96,417.71</b>
<b>II. ASSETS</b>		
<b>(I) Non-current assets</b>		
<b>(a) Fixed assets</b>		
(i) Tangible assets	36,025.09	35,104.33
(ii) Intangible assets	1,295.42	-
(iii) Capital work-in-progress	14,541.38	10,092.36
	<b>51,861.89</b>	<b>45,196.69</b>
(b) Non-current Investment	9,561.88	8,322.02
(c) Long term loans and advances	2,864.26	2,583.52
<b>(2) Current assets</b>		
(a) Current Investments	2,502.79	1,600.81
(b) Inventories	14,451.69	12,009.10
(c) Trade receivables	20,388.73	19,764.21
(d) Cash & Bank Balances	422.45	583.46
(e) Short term Loans and advances	6,570.06	5,910.34
(f) Other current assets	387.19	447.56
	<b>44,722.91</b>	<b>40,315.48</b>
<b>TOTAL ASSETS</b>	<b>109,010.94</b>	<b>96,417.71</b>

5 Previous years figures have been regrouped / recast / reclassified wherever necessary.

By Order of the Board  
For Unichem Laboratories Limited

Place: Mumbai  
Date: 20th October, 2012

Dr. Prakash A. Mody  
Chairman & Managing Director

**LIMITED REVIEW REPORT**


The Board of Directors  
M/s. Unichem Laboratories Ltd.  
Mumbai

We have reviewed the accompanying statement of unaudited financial results of M/s. Unichem Laboratories Limited for quarter / half year ended 30<sup>th</sup> September 2012 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and has not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors / Audit Committee. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, engagements to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our notice that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of clause 4i of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For B. D. Jokhakar & Co.  
Chartered Accountants  
Firm Registration No.: 104345W



Raman Jokhakar  
Partner  
Membership No. 103241



Date: 20<sup>th</sup> October, 2012